Form 8-K - Current report:
SEC Accession No. 0001104659-26-020667
Filing Date
2026-02-26
Accepted
2026-02-26 17:31:11
Documents
15
Period of Report
2026-02-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2534019d6_8k.htm   iXBRL 8-K 30267
2 EXHIBIT 1.1 tm2534019d6_ex1-1.htm EX-1.1 279870
3 EXHIBIT 5.1 tm2534019d6_ex5-1.htm EX-5.1 13328
7 GRAPHIC tm2534019d6_ex5-1img001.jpg GRAPHIC 13563
  Complete submission text file 0001104659-26-020667.txt   584662

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA pvla-20260225.xsd EX-101.SCH 3020
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pvla-20260225_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pvla-20260225_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2534019d6_8k_htm.xml XML 3214
Mailing Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087
Business Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087 (484) 253-1461
PALVELLA THERAPEUTICS, INC. (Filer) CIK: 0001583648 (see all company filings)

EIN.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37471 | Film No.: 26690697
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)